Long has served as the head of the chemistry department at ACEA Therapeutics, Inc. since 2009. He is responsible for drug design, medicinal chemistry, CMC drug substance (active pharmaceutical ingredient) manufacturing process development, and company intellectual properties (IP). He structurally designed both drug molecules of AC0010MA (abivertinib maleate) and AC0058TA, and led the team in chemical process development scale up from the med-chem lab to commercial manufacturing.

Prior to joining ACEA, Long was a senior research investigator at TorreyPines Therapeutics, Inc., where he led the research and discovery of NGX555, the first experimental small molecule drug as Amyloid Beta γ-Secretase Modulator for the treatment of Alzheimer diseases. He was also a key contributor to the design of NGX 426, a novel pro-drug of Tezampanel and potent and selective AMPA/Kainate receptor antagonist. At Bristol-Myers Squibb Company/DuPont Pharmaceutical Research Laboratories (formerly CombiChem, Inc.), Long was a research scientist, where he worked on several small molecule drug discovery and development programs, such as CRF receptor antagonists, CCR3 receptor antagonists, and Matrix Metalloproteinase (MMP-3 and MMP-13) inhibitors. He has over 20 years of hands-on experience in the pharmaceutical industry, and over 20 US patents granted.

Long received his master degrees from University of California at Davis and Zhejiang University, majoring in bio-organic chemistry and physical chemistry, respectively.